Amneal Pharmaceuticals Inc (NYSE:AMRX) – Equities research analysts at SunTrust Banks boosted their Q4 2018 earnings per share estimates for Amneal Pharmaceuticals in a research report issued on Monday, November 5th. SunTrust Banks analyst J. Boris now anticipates that the company will post earnings of $0.31 per share for the quarter, up from their prior forecast of $0.30. SunTrust Banks currently has a “Hold” rating and a $15.00 price target on the stock.
Amneal Pharmaceuticals (NYSE:AMRX) last issued its quarterly earnings data on Wednesday, November 7th. The company reported $0.28 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.01. Amneal Pharmaceuticals had a positive return on equity of 6.62% and a negative net margin of 36.54%. The company had revenue of $476.50 million during the quarter, compared to analyst estimates of $486.01 million. The business’s revenue was up 87.1% compared to the same quarter last year.
Shares of AMRX opened at $19.75 on Thursday. The company has a debt-to-equity ratio of 2.85, a current ratio of 2.01 and a quick ratio of 1.25. Amneal Pharmaceuticals has a one year low of $13.47 and a one year high of $24.48. The firm has a market capitalization of $6.14 billion, a P/E ratio of 32.67, a PEG ratio of 1.01 and a beta of 1.56.
Several institutional investors have recently made changes to their positions in AMRX. Fosun International Ltd purchased a new position in shares of Amneal Pharmaceuticals in the second quarter valued at about $333,013,000. FMR LLC purchased a new position in shares of Amneal Pharmaceuticals in the second quarter valued at about $130,351,000. BlackRock Inc. purchased a new position in shares of Amneal Pharmaceuticals in the second quarter valued at about $95,312,000. TPG Group Holdings SBS Advisors Inc. purchased a new position in shares of Amneal Pharmaceuticals in the second quarter valued at about $67,438,000. Finally, TCW Group Inc. purchased a new position in shares of Amneal Pharmaceuticals in the second quarter valued at about $42,390,000. Institutional investors and hedge funds own 31.84% of the company’s stock.
In other Amneal Pharmaceuticals news, CFO Bryan M. Reasons sold 11,698 shares of the business’s stock in a transaction dated Tuesday, August 21st. The stock was sold at an average price of $23.65, for a total transaction of $276,657.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Nikita Shah sold 50,000 shares of the business’s stock in a transaction dated Tuesday, August 21st. The shares were sold at an average price of $23.46, for a total value of $1,173,000.00. The disclosure for this sale can be found here. Insiders own 3.20% of the company’s stock.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.
Featured Article: Hedge Funds – How They Work For Investors
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.